دورية أكاديمية
أعرض في EDS

Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis.

التفاصيل البيبلوغرافية
العنوان: Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis.
المؤلفون: Kimuda S; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Kasozi D; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Namombwe S; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Gakuru J; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Mugabi T; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Kagimu E; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Rutakingirwa MK; Infectious Diseases Institute, Makerere University, Kampala, Uganda., Leon KE; Departments of Neurology and Medicine (Infectious Diseases), University of California San Francisco, San Francisco, CA, USA., Chow F; Departments of Neurology and Medicine (Infectious Diseases), University of California San Francisco, San Francisco, CA, USA., Wasserman S; Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Boulware DR; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA., Cresswell FV; Infectious Diseases Institute, Makerere University, Kampala, Uganda.; HIV Interventions, MRC/UVRI-LSHTM Uganda Research Unit, Entebbe, Uganda.; Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK., Bahr NC; Division of Infectious Diseases, Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Nbahr@kumc.edu.
المصدر: Current HIV/AIDS reports [Curr HIV/AIDS Rep] 2023 Dec; Vol. 20 (6), pp. 379-393. Date of Electronic Publication: 2023 Nov 10.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Current Science Country of Publication: United States NLM ID: 101235661 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1548-3576 (Electronic) Linking ISSN: 15483568 NLM ISO Abbreviation: Curr HIV/AIDS Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Current Science
مواضيع طبية MeSH: Tuberculosis, Meningeal*/diagnosis , Tuberculosis, Meningeal*/drug therapy , Tuberculosis, Meningeal*/microbiology , Mycobacterium tuberculosis*/genetics , HIV Infections*/complications , HIV Infections*/diagnosis , HIV Infections*/drug therapy , Tuberculosis, Pulmonary*/drug therapy, Humans ; Rifampin/therapeutic use ; Sensitivity and Specificity
مستخلص: Purpose of Review: Tuberculous meningitis (TBM) is the most severe form of tuberculosis. Inadequate diagnostic testing and treatment regimens adapted from pulmonary tuberculosis without consideration of the unique nature of TBM are among the potential drivers. This review focuses on the progress being made in relation to both diagnosis and treatment of TBM, emphasizing promising future directions.
Recent Findings: The molecular assay GeneXpert MTB/Rif Ultra has improved sensitivity but has inadequate negative predictive value to "rule-out" TBM. Evaluations of tests focused on the host response and bacterial components are ongoing. Clinical trials are in progress to explore the roles of rifampin, fluoroquinolones, linezolid, and adjunctive aspirin. Though diagnosis has improved, novel modalities are being explored to improve the rapid diagnosis of TBM. Multiple ongoing clinical trials may change current therapies for TBM in the near future.
(© 2023. The Author(s).)
References: Int J Tuberc Lung Dis. 2021 Aug 1;25(8):626-631. (PMID: 34330347)
mBio. 2017 Aug 29;8(4):. (PMID: 28851844)
Int J Tuberc Lung Dis. 2015 Oct;19(10):1209-15. (PMID: 26459535)
PLoS One. 2012;7(6):e38982. (PMID: 22768055)
Front Cell Infect Microbiol. 2022 Apr 22;12:788692. (PMID: 35531329)
Lancet. 2018 Jul 28;392(10144):292-301. (PMID: 30032978)
Biosci Rep. 2020 Jan 31;40(1):. (PMID: 31778149)
Lancet HIV. 2023 Jul;10(7):e433-e441. (PMID: 37230101)
J Pediatric Infect Dis Soc. 2021 Dec 31;10(12):1087-1091. (PMID: 34608937)
Int J Infect Dis. 2010 Jul;14(7):e586-91. (PMID: 20005759)
Cochrane Database Syst Rev. 2021 Jan 15;1:CD012768. (PMID: 33448348)
Pharmacol Rep. 2010 May-Jun;62(3):518-25. (PMID: 20631416)
Wellcome Open Res. 2020 Dec 23;5:292. (PMID: 35118196)
N Engl J Med. 2004 Oct 21;351(17):1741-51. (PMID: 15496623)
J Neuroimaging. 2019 Sep;29(5):657-668. (PMID: 31115112)
PLOS Glob Public Health. 2021 Dec 8;1(12):e0000069. (PMID: 36962116)
Ochsner J. 2014 Summer;14(2):203-7. (PMID: 24940130)
Sex Transm Infect. 2018 Sep;94(6):420. (PMID: 30030303)
Front Neurol. 2022 May 30;13:892224. (PMID: 35711276)
J Clin Microbiol. 2014 Oct;52(10):3777-80. (PMID: 25056328)
Microbiol Spectr. 2022 Aug 31;10(4):e0161822. (PMID: 35727068)
Clin Infect Dis. 2013 Feb;56(3):450-60. (PMID: 23097584)
Bull World Health Organ. 1950;3(2):215-64. (PMID: 14792272)
Neurol India. 2018 Nov-Dec;66(6):1672-1677. (PMID: 30504561)
Clin Pharmacol Ther. 2020 Apr;107(4):1023-1033. (PMID: 31956998)
Lancet Neurol. 2013 Oct;12(10):999-1010. (PMID: 23972913)
J Infect Dis. 2005 Jul 1;192(1):79-88. (PMID: 15942897)
Open Forum Infect Dis. 2020 Dec 28;8(1):ofaa604. (PMID: 33542942)
Biomarkers. 2022 Sep;27(6):549-561. (PMID: 35506251)
PLoS One. 2022 Aug 30;17(8):e0273834. (PMID: 36040925)
Int J Tuberc Lung Dis. 2009 Feb;13(2):269-71. (PMID: 19146759)
Biomark Med. 2018 Jul;12(7):707-716. (PMID: 29856234)
J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S270-3. (PMID: 25768866)
J Clin Microbiol. 2019 May 24;57(6):. (PMID: 30944198)
J Interferon Cytokine Res. 2022 Mar;42(3):95-107. (PMID: 35298290)
Int J Tuberc Lung Dis. 2022 Apr 1;26(4):317-325. (PMID: 35351236)
J Infect. 2018 Dec;77(6):509-515. (PMID: 30217659)
Tuberculosis (Edinb). 2022 Jul;135:102230. (PMID: 35779498)
Wellcome Open Res. 2019 Dec 2;4:190. (PMID: 33083560)
J Mol Histol. 2015 Oct;46(4-5):439-42. (PMID: 26208572)
N Engl J Med. 2023 Oct 12;389(15):1357-1367. (PMID: 37819954)
Wellcome Open Res. 2019 Nov 5;4:167. (PMID: 32118118)
Wellcome Open Res. 2019 Aug 19;4:123. (PMID: 31544160)
Lancet Infect Dis. 2020 Mar;20(3):308-317. (PMID: 31924549)
Tuberculosis (Edinb). 2010 Nov;90(6):367-74. (PMID: 20880749)
Biopharm Drug Dispos. 2017 May;38(4):301-312. (PMID: 28092695)
Lancet. 2002 Oct 26;360(9342):1287-92. (PMID: 12414204)
J Med Microbiol. 2019 May;68(5):755-760. (PMID: 30994435)
Antimicrob Agents Chemother. 2013 Mar;57(3):1218-30. (PMID: 23263006)
J Infect. 2009 Sep;59(3):167-87. (PMID: 19643501)
J Med Chem. 2010 Apr 8;53(7):2882-91. (PMID: 20205479)
Clin Infect Dis. 2021 Sep 7;73(5):876-884. (PMID: 33693537)
J Neurol. 2019 Dec;266(12):3009-3021. (PMID: 31485723)
Clin Infect Dis. 2017 Jul 1;65(1):20-28. (PMID: 28472255)
Clin Infect Dis. 2011 Jun;52(11):1374-83. (PMID: 21596680)
Elife. 2023 May 09;12:. (PMID: 37158692)
J Antimicrob Chemother. 2022 May 29;77(6):1720-1724. (PMID: 35257182)
Open Forum Infect Dis. 2018 Jan 30;5(2):ofy027. (PMID: 29507866)
Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):471-6. (PMID: 15141333)
Lancet HIV. 2022 Apr;9(4):e233-e241. (PMID: 35338834)
J Leukoc Biol. 2019 Feb;105(2):267-280. (PMID: 30645042)
Int J STD AIDS. 2020 Jul;31(8):808-812. (PMID: 32631210)
Nat Commun. 2022 Mar 30;13(1):1675. (PMID: 35354815)
Open Forum Infect Dis. 2022 Apr 09;9(6):ofac108. (PMID: 35673608)
Antimicrob Agents Chemother. 2019 Sep 23;63(10):. (PMID: 31383662)
Trop Med Int Health. 2021 Feb;26(2):122-132. (PMID: 33164243)
Emerg Microbes Infect. 2019;8(1):1361-1369. (PMID: 31522608)
Xenobiotica. 2016;46(3):247-52. (PMID: 26207565)
Front Pharmacol. 2023 Feb 02;14:1100488. (PMID: 36817137)
J Antimicrob Chemother. 2014 Sep;69(9):2310-8. (PMID: 24860154)
Clin Infect Dis. 2021 Mar 1;72(5):e136-e145. (PMID: 33283220)
Int J Mycobacteriol. 2020 Jul-Sep;9(3):303-308. (PMID: 32862165)
Am J Trop Med Hyg. 2020 Mar;102(3):562-566. (PMID: 31971152)
Nat Rev Neurol. 2017 Oct;13(10):581-598. (PMID: 28884751)
Clin Pharmacokinet. 2013 Jul;52(7):511-42. (PMID: 23605634)
Nat Commun. 2019 Aug 21;10(1):3767. (PMID: 31434901)
Lancet Infect Dis. 2019 Aug;19(8):852-861. (PMID: 31155318)
BMC Infect Dis. 2020 May 7;20(1):325. (PMID: 32380957)
Clin Infect Dis. 2021 Nov 2;73(9):e3428-e3434. (PMID: 33388751)
Clin Infect Dis. 2016 May 1;62(9):1133-5. (PMID: 26966284)
Curr HIV/AIDS Rep. 2009 Aug;6(3):139-45. (PMID: 19589299)
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):230-8. (PMID: 21239993)
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 15;988:187-94. (PMID: 25796075)
Clin Microbiol Rev. 2011 Apr;24(2):351-76. (PMID: 21482729)
Clin Infect Dis. 2020 Nov 5;71(8):2002-2005. (PMID: 32543658)
Clin Infect Dis. 2022 Oct 29;75(9):1594-1601. (PMID: 35291004)
Int J Tuberc Lung Dis. 2002 Oct;6(10):865-71. (PMID: 12365572)
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. (PMID: 12588714)
Lancet Infect Dis. 2018 Jan;18(1):68-75. (PMID: 28919338)
N Engl J Med. 1992 Mar 5;326(10):668-72. (PMID: 1346547)
J Antimicrob Chemother. 2015 Jan;70(1):225-32. (PMID: 25239466)
Lancet Infect Dis. 2010 Nov;10(11):803-12. (PMID: 20822958)
Int J Tuberc Lung Dis. 2016 May;20(5):625-30. (PMID: 27084816)
Clin Infect Dis. 2020 Nov 5;71(8):1817-1823. (PMID: 31665299)
Lancet Glob Health. 2023 Jun;11(6):e903-e916. (PMID: 37202025)
J Infect. 2017 Jun;74(6):545-554. (PMID: 28366687)
Diagn Microbiol Infect Dis. 2018 May;91(1):42-46. (PMID: 29444749)
Br Med J (Clin Res Ed). 1987 Jan 31;294(6567):284-5. (PMID: 3101843)
N Engl J Med. 2016 Jan 14;374(2):124-34. (PMID: 26760084)
Int J Tuberc Lung Dis. 2010 Nov;14(11):1382-7. (PMID: 20937176)
J Child Neurol. 2011 Aug;26(8):956-62. (PMID: 21628697)
Clin Infect Dis. 2022 Sep 10;75(4):682-689. (PMID: 34849645)
Trop Med Int Health. 2023 Mar;28(3):175-185. (PMID: 36591905)
BMC Infect Dis. 2021 Sep 28;21(1):1015. (PMID: 34583653)
Int J Antimicrob Agents. 2018 Jan;51(1):77-81. (PMID: 28843822)
J Clin Microbiol. 2019 Jul 26;57(8):. (PMID: 31189584)
J Neurol Sci. 2010 Jun 15;293(1-2):12-7. (PMID: 20421121)
Open Forum Infect Dis. 2020 Jun 30;7(8):ofaa257. (PMID: 32818138)
Lancet Infect Dis. 2013 Jan;13(1):27-35. (PMID: 23103177)
Cochrane Database Syst Rev. 2016 Apr 28;4:CD002244. (PMID: 27121755)
J Clin Microbiol. 2011 May;49(5):1861-5. (PMID: 21411583)
Indian J Med Res. 2019 Aug;150(2):131-138. (PMID: 31670268)
Lancet. 2001 May 12;357(9267):1519-23. (PMID: 11377627)
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab345. (PMID: 34307735)
Int J Infect Dis. 2016 Jul;48:64-9. (PMID: 27173078)
Lancet Infect Dis. 2020 Mar;20(3):299-307. (PMID: 31924551)
Elife. 2018 Feb 27;7:. (PMID: 29482717)
Med Clin North Am. 2017 Jul;101(4):713-724. (PMID: 28577622)
Med. 2022 Sep 9;3(9):603-611.e2. (PMID: 36041428)
معلومات مُعتمدة: K23 NS110470 United States NS NINDS NIH HHS; R01 AI162786 United States AI NIAID NIH HHS; R01 AI170158 United States AI NIAID NIH HHS; K43 TW011421 United States TW FIC NIH HHS; U01 AI170426 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Central nervous system infection; Diagnostic tests; TB; Tuberculosis; Tuberculous meningitis
المشرفين على المادة: VJT6J7R4TR (Rifampin)
تواريخ الأحداث: Date Created: 20231110 Date Completed: 20231216 Latest Revision: 20240529
رمز التحديث: 20240529
مُعرف محوري في PubMed: PMC10719136
DOI: 10.1007/s11904-023-00678-6
PMID: 37947980
قاعدة البيانات: MEDLINE
الوصف
تدمد:1548-3576
DOI:10.1007/s11904-023-00678-6